Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Stotz, M; Herzog, SA; Pichler, M; Smolle, M; Riedl, J; Rossmann, C; Bezan, A; Stöger, H; Renner, W; Berghold, A; Gerger, A.
Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients.
Anticancer Res. 2017; 37(4):2011-2018
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Berghold Andrea
Gerger Armin
Herzog Sereina Annik
Pichler Martin
Renner Wilfried
Riedl Jakob
Roßmann Christopher
Smolle Maria
Stoeger Herbert
Stotz Michael
Terbuch Angelika
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Growing evidence suggests that human cancers are stem cell diseases and recent data support the existence of cancer stem cells (CSCs) in a variety of malignancies, including colon cancer. These CSCs were shown to be capable of initiating tumor development and progression. Several studies have suggested CD133, CD26 and CD44 as markers of tumor-initiating cells of colon cancer. The purpose of the present study was to assess the impact of single-nucleotide polymorphisms (SNPs) in stem cell-related genes on clinical outcome in a large cohort of colon cancer patients with clinical stage II and III. Data from 599 consecutive patients with colon cancer stage II and III, treated between 1995 and 2011 at a single centre, were retrospectively evaluated. Genomic DNA was extracted from paraffin-embedded normal tissue distant from the tumor to obtain germline DNA. Allelic distribution of polymorphisms was tested for deviation from Hardy-Weinberg equilibrium using χ2-test. The association of polymorphisms with time to recurrence (TTR) and overall survival (OS) was analyzed using Kaplan-Meier curves and compared by the log-rank test. Case-wise deletion for missing polymorphisms was used in univariable and multivariable analyses. CD44 rs187115 showed a statistically significant association with TTR; patients carrying at least one G allele had a significant reduced risk of recurrence compared to patients with the homozygous A/A variant (hazard ratio (HR)=0.67, 95% confidence interval (CI)=0.48-0.94, p=0.019). CD44 rs13347 showed a statistically significant association with OS. Patients carrying at least one T allele in rs13347 had a significantly reduced risk of death compared to patients with the homozygous C/C variant (HR=0.61, 95% CI=0.41-0.92, p=0.019). None of the other investigated polymorphisms (CD44 rs187116, CD44 rs7116432, CD44 rs353639, DPP4 rs2268889, DPP4 rs3788979, DPP4 rs7608798 and CD133 rs2240688) were associated with either TTR or OS. Germline variants rs13347 and rs187115 in the stem cell gene CD44 are prognostically relevant in stage II and III colon cancer patients. Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Aged -
Aged, 80 and over -
Biomarkers, Tumor - genetics
Colonic Neoplasms - genetics
Colonic Neoplasms - pathology
Female -
Follow-Up Studies -
Genotype -
Humans -
Hyaluronan Receptors - genetics
Male -
Middle Aged -
Neoplasm Grading -
Neoplasm Invasiveness -
Neoplasm Recurrence, Local - genetics
Neoplasm Recurrence, Local - pathology
Neoplasm Staging -
Neoplastic Stem Cells - metabolism
Neoplastic Stem Cells - pathology
Polymorphism, Single Nucleotide - genetics
Prognosis -
Retrospective Studies -
Survival Rate -

Find related publications in this database (Keywords)
Colon cancer
single-nucleotide polymorphisms
cancer stem cells
CD44
© Med Uni Graz Impressum